{"contentid": 487940, "importid": NaN, "name": "$107 million write off follows failure of PAH drug Trevyent", "introduction": "A regulatory filing in the USA reveals that United Therapeutics will drop development of Trevyent (treprostinil), an experimental pulmonary arterial hypertension (PAH) drug.", "content": "<p><span style=\"font-weight: 400;\">A </span><a href=\"https://d18rn0p25nwr6d.cloudfront.net/CIK-0001082554/29718de9-28e6-4f08-a107-d3170b3439e3.pdf\"><span style=\"font-weight: 400;\">regulatory filing</span></a><span style=\"font-weight: 400;\"> in the USA reveals that United Therapeutics (Nasdaq: UTHR) will drop development of Trevyent (treprostinil), an experimental pulmonary arterial hypertension (PAH) drug.</span></p>\n<p><span style=\"font-weight: 400;\">Shares in the firm slipped 2% following the announcement, although it was not unexpected, given previous negative feedback from the US regulator, including a Complete Response Letter (CRL) in 2020.</span></p>\n<p><span style=\"font-weight: 400;\">The final decision to pull the plug came after a Food and Drug Administration meeting in which United discussed plans for a resubmission.</span></p>\n<p><span style=\"font-weight: 400;\">The regulator indicated it would have to redesign and then retest the drug-device combination product, with the goal of improving pump accuracy.</span></p>\n<p><span style=\"font-weight: 400;\">In its filing with The US Securities and Exchange Commission (SEC), the firm stated: &ldquo;These additional steps would have caused considerable additional delay, and additional development efforts may not ultimately be successful in addressing the FDA&rsquo;s comments.&rdquo;</span></p>\n<p><span style=\"font-weight: 400;\">&ldquo;The company decided that continued development of Trevyent was no longer commercially reasonable in light of this additional FDA feedback,&rdquo; the firm said.</span></p>\n<p><span style=\"font-weight: 400;\">United picked up the program through its $215 million acquisition of specialty Israeli pharma firm SteadyMed in 2018.</span></p>\n<p><span style=\"font-weight: 400;\">Now, following its failure, the company said it expected to have to write off over $100 million in the first quarter, through an impairment charge.</span></p>\n<p><span style=\"font-weight: 400;\">United will now move forward with a new formulation of Tyvaso (treprostinil), the company&rsquo;s inhalable version of treprostinil for PAH.</span></p>", "date": "2021-03-04 10:40:00", "meta_title": NaN, "meta_keywords": "United, Trevyent, development, drug, treprostinil, firm, additional, filing, million, regulatory, failure, reveals, Therapeutics, write, hypertension, drop", "meta_description": "A regulatory filing in the USA reveals that United Therapeutics will drop development of Trevyent (treprostinil), an experimental pulmonary arterial hypertensio", "meta_robots": NaN, "meta_display_in_sitemap": 1, "canonical_url": NaN, "status": 1, "access_status": 0, "ignore_flexible_sampling": 0, "display_start_date": "0000-00-00 00:00:00", "display_end_date": "0000-00-00 00:00:00", "display_in_search": 1, "created": "2021-03-04 10:39:53", "updated": "2021-03-04 10:50:11", "access": NaN, "url": "https://www.thepharmaletter.com/article/107-million-write-off-follows-failure-of-pah-drug-trevyent", "description": NaN, "twitter_term": NaN, "twitter_widgetid": NaN, "key_facts": NaN, "news_snippet": NaN, "image1id": "united_therapeutics_large.jpg", "image2id": "united_therapeutics_small.jpg", "restrict_print": 0, "restrict_print_for_logged_out": 0, "box1_header": NaN, "box1_title": NaN, "box1_image1id": 0, "box1_url": NaN, "box1_introduction": NaN, "box1_position": 0, "tags": NaN, "sector_tag": "Pharmaceutical", "therapy area_tag": "Respiratory and Pulmonary", "topic_tag": "Focus On, Management, Regulation, Research, US FDA", "geography_tag": "USA", "company_tag": "United Therapeutics", "drug_tag": "Trevyent, Tyvaso", "market index_tag": NaN, "theme_tag": NaN, "industry sector_tag": NaN, "medical condition_tag": NaN, "industry term_tag": NaN, "organization_tag": NaN, "person_tag": NaN, "position_tag": NaN, "medical treatment_tag": NaN, "facility_tag": NaN, "technology_tag": NaN, "journalist_tag": NaN, "published medium_tag": NaN, "political event_tag": NaN, "anniversary_tag": NaN, "sports event_tag": NaN, "movie_tag": NaN, "fax number_tag": NaN, "currency pair_tag": NaN, "sports league_tag": NaN, "date_tag": NaN, "music group_tag": NaN, "phone number_tag": NaN, "t v show_tag": NaN, "t v station_tag": NaN, "entertainment award event_tag": NaN, "industry_tag": NaN, "pharmaceutical drug_tag": NaN, "topmost public parent company_tag": NaN, "content_type_name": "Article", "pubDate": "2021-03-04 10:40:00"}